drugset / Trial / NCT05716880

Ketoanalogues for Muscle Mass Loss in Nephrotic Syndrome

NCT05716880 ↗

RandomizedParallel-groupOpen-labelSupportive care

Summary

The goal of this non-commercial clinical trial is to assess efficacy and safety of ketoanalogues of essential amino acids in the prevention of protein-energy wasting in nephrotic syndrome.

Timeline

Start
2023-01-03
Primary completion
2027-02-28
Completion
2027-08-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Ketosteril Unknown 1 unknown —

Indications